Top 5 FDA-Approved Treatments for Breast Cancer
Discover the top five FDA-approved medications for breast cancer, including Afinitor, Piqray, Nerlynx, Kisqali, and Ibrance. These targeted therapies play a crucial role in managing different breast cancer types, improving patient outcomes through advanced treatment options. Early detection combined with these medications offers hope for effective disease control and recovery.
Top 5 FDA-Approved Drugs for Breast Cancer
Breast cancer is one of the most common cancers among women, second only to skin cancer. It originates in breast tissue cells and, although more prevalent in women, can also affect men. The exact causes remain unknown, but genetics play a significant role, and environmental factors might contribute. Early detection through routine mammograms and examinations significantly improves prognosis. Symptoms include breast lumps, changes in size or shape, skin alterations, nipple inversion, or skin irritation. Early diagnosis enables effective treatment options. Treatments often involve specific medications including the following:
Afinitor® Also called Afinitor Disperz®, this drug hampers cancer cell growth by disrupting their division cycle. It’s used not only in breast cancer but also for certain kidney cancers and brain tumors. Additionally, Afinitor® treats advanced tumors in the pancreas, stomach, and intestines, and manages some brain and kidney tumors related to tuberous sclerosis complex.
Piqray® Known chemically as Alpelisib, Piqray® belongs to the PI3K inhibitor class. It blocks the overactive PI3K pathway in cancer cells, starving them of energy. Used alongside other treatments, it targets hormone-receptor-positive, HER2-negative metastatic breast cancer with PIK3CA mutations, especially in postmenopausal women and men after hormonal therapy fails.
Nerlynx® With the active ingredient neratinib, this kinase inhibitor is approved for extended therapy in early-stage HER2-positive breast cancer post-surgery. It works by hindering cancer cell proliferation, helping prevent recurrence in women previously treated with trastuzumab (Herceptin).
Kisqali® Chemically known as ribociclib, Kisqali® targets cyclin-dependent kinases (CDKs) critical for cancer growth. Recommended for postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, it’s used alongside hormone therapies to improve outcomes.
Ibrance® Also called palbociclib, Ibrance® is prescribed for metastatic breast cancer that is ER-positive and HER2-negative, especially in women who haven't had prior treatment. It works by blocking enzymes essential for cancer cell division, reducing tumor progression.
